Header Logo

Connection

Jonathan Kay to Magnetic Resonance Imaging

This is a "connection" page, showing publications Jonathan Kay has written about Magnetic Resonance Imaging.
Connection Strength

0.643
  1. Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging. 2009 Dec; 30(6):1335-40.
    View in: PubMed
    Score: 0.177
  2. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009 Oct; 253(1):81-9.
    View in: PubMed
    Score: 0.174
  3. Schaub S, Sirkis HM, Kay J. Imaging for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome. Rheum Dis Clin North Am. 2016 11; 42(4):695-710.
    View in: PubMed
    Score: 0.071
  4. Lima XT, Alora-Palli MB, Kimball AB, Kay J. Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):637-42.
    View in: PubMed
    Score: 0.056
  5. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011 Jul; 260(1):105-11.
    View in: PubMed
    Score: 0.049
  6. Kay J, Czirj?k L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis. 2010 Nov; 69(11):1895-7.
    View in: PubMed
    Score: 0.047
  7. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med. 2008 Feb; 75(2):112, 114, 117.
    View in: PubMed
    Score: 0.039
  8. Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landew? R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 07; 71(7):1101-1111.
    View in: PubMed
    Score: 0.021
  9. Cha JH, Furie K, Kay J, Walensky RP, Mullins ME, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. N Engl J Med. 2006 Dec 21; 355(25):2678-89.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.